Diagnosis and Management of Cutaneous Psoriasis: A Review

Brandon, Alisa; Mufti, Asfandyar; Sibbald, R. Gary

doi:10.1097/01.asw.0000550592.08674.43

Cited by 63 publications

(60 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although there is no cure for psoriasis, there are well-established management protocols. The first line therapy for mild and moderate psoriasis is usually topical therapy that involves a combination of glucocorticoids, vitamin D analogues, and phototherapy, while that for moderate to severe psoriasis often requires systemic therapy [2][3][4]. Drugs used in systemic therapy for psoriasis include both small molecules such as methotrexate (MTX), retinoids, or cyclosporin, and more recently, biologics such as monoclonal antibodies and receptor fusion proteins.…”

Section: Introductionmentioning

confidence: 99%

Topical Application of Mesenchymal Stem Cell Exosomes Alleviates the Imiquimod Induced Psoriasis-Like Inflammation

Zhang

Lai

Sim

et al. 2021

IJMS

View full text Add to dashboard Cite

Severe psoriasis, a chronic inflammatory skin disease is increasingly being effectively managed by targeted immunotherapy but long-term immunotherapy poses health risk and loss of response. Therefore, there is a need for alternative therapy strategies. Mesenchymal stem/stromal cell (MSC) exosomes are widely known for their potent immunomodulatory properties. Here we investigated if topically applied MSC exosomes could alleviate psoriasis-associated inflammation. Topically applied fluorescent exosomes on human skin explants were confined primarily to the stratum corneum with <1% input fluorescence exiting the explant over a 24-h period. Nevertheless, topically applied MSC exosomes in a mouse model of imiquimod (IMQ) psoriasis significantly reduced IL-17 and terminal complement activation complex C5b-9 in the mouse skin. MSC exosomes were previously shown to inhibit complement activation, specifically C5b-9 complex formation through CD59. Infiltration of neutrophils into the stratum corneum is characteristic of psoriasis and neutrophils are a major cellular source of IL-17 in psoriasis through the release of neutrophil extracellular traps (NETs). We propose that topically applied MSC exosomes inhibit complement activation in the stratum corneum and this alleviates IL-17 release by NETS from neutrophils that accumulate in and beneath the stratum corneum.

show abstract

Section: Introductionmentioning

confidence: 99%

Topical Application of Mesenchymal Stem Cell Exosomes Alleviates the Imiquimod Induced Psoriasis-Like Inflammation

Zhang

Lai

Sim

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…Psoriasis is a chronic, immune‐mediated skin disease, which has a strong genetic and polygenic basis 1 . Many factors affect the morbidity of this disease, including polygenetic change, specific gene activation and complicated pathological changes, making the disease difficult to cure 2‐9 .…”

Section: Introductionmentioning

confidence: 99%

Discovering novel hub genes and pathways associated with the pathogenesis of psoriasis

Gao

Shen

Ren

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

In-depth analysis on the rambling genes of psoriasis may help to identify the pathologic mechanism of this disease. However, this has seldom been performed. Using bioinformatic approaches, we analyzed four gene expression profiles in gene expression omnibus (GEO) database, identified the differentially expressed genes (DEGs), and found out the overlapping DEGs (common DEGs, CDEGs) in the above four profiles. The CDEGs were further subjected to Gene Ontology (GO) enrichment analysis, Kyoto encyclopedia of genes and genomes (KEGG) pathway analysis and proteinprotein interaction (PPI) network analysis, and hub genes were ranked. We identified 139 CDEGs associated with a variety of GO processes including keratinization, immune and inflammatory responses, and type 1 interferon signaling pathway. These CDEGs were enriched in a variety of KEGG processes, including cytokine-cytokine receptor interaction and chemokine signaling. PPI analysis showed that seven genes (HERC6, ISG15, MX1, RSAD2, OAS2, OASL, and OAS3) were likely the novel hub genes of psoriasis. RT-qPCR identified that five (ISG15, MX1, OAS2, OASL, and OAS3) of the seven predicted hub genes were overexpressed in TNF-α stimulated HaCaT cell lines, a result quite consistent with the predictions. The study provides new information in exploring the mechanisms and therapeutic targets of psoriasis.

show abstract

“…Psoriasis is a chronic, visible, immune-mediated psychocutaneous disease, which can impact considerably the patient’s life quality and their daily functioning (Yadav et al, 2013; França et al, 2017). This skin condition is characterized by circumscribed, erythematous, dry, scaly plaques and has a fluctuating severity over time (Reich, 2012; Brandon et al, 2019). A range of co-morbidities is associated with psoriasis, including cardiovascular disease, diabetes, obesity, metabolic syndrome, and common psychological disorders like depression and anxiety (Picardi et al, 2004; Gisondi et al, 2013; Miller et al, 2013; Lakshmy et al, 2015; Linder et al, 2015).…”

Section: Introductionmentioning

confidence: 99%

Expressive Suppression and Negative Affect, Pathways of Emotional Dysregulation in Psoriasis Patients

2019

View full text Add to dashboard Cite

The main goal of this study was to assess the emotion regulation (ER) mechanisms, such as expressive suppression and cognitive reappraisal, in patients with psoriasis, as compared with healthy persons not afflicted by dermatological diseases. Moreover, the study intended to carry on a multidimensional assessment of emotional mechanisms in persons with psoriasis, highlighting the differences between psoriasis patients and healthy participants, in order to identify the specific patterns of emotion dysregulation (ED) in psoriasis. Another goal of the study was to investigate the predictors of ED among different emotional patterns. We presumed that the maladaptive ER mechanisms are higher in psoriasis patients than in the control group and there are specific dysregulation patterns in psoriasis patients as negative emotions tendency. This cross-sectional study was performed on 192 individuals aged between 35 and 75 years (mean age 59). The sample was divided in two groups: the clinical group including 91 patients with a diagnosis of psoriasis vulgaris and the control group including 101 healthy persons. The results of the present study suggest that psoriasis patients more frequently used emotional suppression – a maladaptive ER mechanism – as well as ED patterns – i.e., impulse control difficulties, and nonacceptance of emotional responses. They also displayed trait tendency to a negative emotional response. In fact, in people with psoriasis, the presence of suppression mechanism and negative affect of trait could predict that 35% of patients will show emotional dysregulated patterns, while living with higher levels of ED. The results of our study are important in the clinical practice, helping clinicians to better understand the emotional vulnerability of people that live with psoriatic disease, and to optimize the disease management and patient care in an interdisciplinary approach.

show abstract

Diagnosis and Management of Cutaneous Psoriasis: A Review

Cited by 63 publications

References 55 publications

Topical Application of Mesenchymal Stem Cell Exosomes Alleviates the Imiquimod Induced Psoriasis-Like Inflammation

Topical Application of Mesenchymal Stem Cell Exosomes Alleviates the Imiquimod Induced Psoriasis-Like Inflammation

Discovering novel hub genes and pathways associated with the pathogenesis of psoriasis

Expressive Suppression and Negative Affect, Pathways of Emotional Dysregulation in Psoriasis Patients

Contact Info

Product

Resources

About